The new crown inactivated vaccine of Koxing Zhongwei, a pharmaceutical speed-reading agency, was approved for sale in China

February 7, 2021 / Medical Information At a Glance: Cochz Zhongwei's new crown inactivated vaccine was approved for listing in China; Torto Bio was officially listed on NASDAQ; and the 4th CAR-T therapy was approved by the FDA... Daily fresh medicine news, speed reading society and you pay attention to! Part1 policy briefing Beijing 6 new cases of foreign importation of new crown pneumonia confirmed cases February 6 from 0:00 to 24:00, Beijing no new local confirmed cases, suspected cases and asymptomatic infected people; 2 new confirmed cases of overseas importation, no new suspected cases, 1 new case of asymptomatic infection; Healed 3 cases discharged from hospital.
case 1 and case 2: February 3 from Papua New Guinea, transit through Hong Kong, China, February 4 arrived at Beijing Capital Airport, customs after health screening and nucleic acid testing, after closed-loop management sent to the centralized isolation hotel, February 5 reported positive test results, respectively, transferred to fixed-point hospitals; The results of comprehensive epidemiological history, clinical manifestations, laboratory testing and imaging examination were all diagnosed as confirmed cases on February 6, and the clinical types were all common.
(CCTV News) 2021 National Health and Health Work Conference: Prepare for the long-term struggle against the new coronavirus The 2021 National Health and Health Work Conference was held in Beijing on February 5.
stressed that a deep understanding of the long-term difficulty of prevention and control of the new coronary pneumonia epidemic, ready to fight the virus for a long time.
to strictly guard against death, to ensure that the outbreak does not appear large-scale input and rebound.
system for surveillance and early warning of infectious diseases, strengthen the infrastructure and capacity-building of the disease control system, and fully mobilize the enthusiasm of institutions and personnel.
deepen the reform of the medical and health system and speed up the construction of a hierarchical diagnosis and treatment system.
prevention and treatment of major diseases, continuously improve medical services, and implement major projects for the revitalization and development of Chinese medicine.
actively respond to the aging of the population, strengthen population monitoring and evaluation, consolidate the implementation of the five systems of maternal and child safety, and strengthen the construction of health services for the elderly.
(Caixin) official message: a number of cottage "Concorde" hospitals will be cleaned up on February 5, the official website of the General Administration of Market Supervision announced that it will carry out a resolute clean-up of well-known hospitals were counterfeited operations, one by one verification in the name of the use of "Concord "Huashan" "Tongji" "Huaxi" "Xiangya" "Chilu" "Tongren" and other well-known hospitals in the name of for-profit medical institutions (including enterprises, individual industrial and commercial households, the same between), severely punish the disruption of the medical market order illegal acts.
(General Administration of Market Supervision) Part2 was officially listed on NASDAQ on February 6th, the industry news came out, Topon Bio was officially listed on NASDAQ on February 5th, U.S. time.
set its IPO price at $17 and will over-issue 7.5 million shares, with an estimated total of $127.5 million before additional options are included.
February 5th was the first day of trading on NASDAQ, according to Lilly Asia Fund's official WeChat.
(Pharmaceutical Mingkangde) Aussie Biopharmaceuticals and Fuhong Hanxuan reached a strategic cooperation intention on February 7, according to the "KoTron Board Daily" reporter was informed that Auscon Biosysconding and Fuhong Hanxuan on February 6 in Nantong Haimen Science and Technology Park signed a letter of intent for strategic cooperation, the two sides on Fuhong Hanxuan research and development to commercial phase of the media production services and CDMO services reached a number of strategic cooperation intentions.
according to the strategic cooperation letter of intent, Auscon has become a preferred supplier to Fuhong Hanxuan, providing the production of culture base GMP services, clinical and commercial production CDMO services.
Recently, Senti Bio announced the completion of a $105 million round B financing, led by Bayer's Bayer Leaps, through China, Mirae Asset Capital, Ridgeback Capital, Intel Capital, and former investment partners New Enterprise Associates, 8VC, Amgen Ventures, and Capital Capital.
it is understood that Senti Bio intends to use the current round of financing to accelerate the development of next-generation cell and gene therapy products.
(arterial network) energy bio to complete 340 million yuan of strategic financing recently, energy bio announced the completion of 340 million yuan of strategic financing.
round of financing led by Qingsong Capital, Pudong Science and Technology, long-established funds, listed companies gorgeous family, Kain energy health and the original shareholder Gaosen assets and other investment.
funding will continue to focus on the research and development of deep and low temperature storage equipment products and iterative upgrading, for automation, intelligent biological sample library, cell library to provide a one-stop overall solution and services.
(Medical Valley) Part3 Drug News FDA accelerated approval of innovative PI3K inhibitors for the treatment of lymphoma TG Therapeutics announced yesterday that the FDA has accelerated approval of Ukoniq for the treatment of patients with recurring/refractic fringe lymphoma who have previously received at least three-line systemic therapy, as well as adult patients with recurring/refractic foam lymphoma who have previously received at least three-line systemic therapy.
press release, Ukoniq was the first approved oral PI3K and CK1.
(Pharmaceutical Minder) Type 4 CAR-T therapy has been approved by the FDA to be approved by the FDA for the listing of breyanzi, a CAR-T therapy developed by Juno Therapeutics of Pershing Mercer, for the treatment of certain adult patients with large B-cell lymphoma.
Breyanzi is a CAR-T cell therapy that targets CD19 antigens and is FDA-approved Type 4 CAR-T therapy.
FDA approved the launch of an innovative prescription medical device developed by Signal Medical Technologies on February 6, the FDA announced that it had approved the launch of an innovative prescription medical device developed by Signifier Medical Technologies to reduce snoring and mild obstructive sleep apnea.
is different from the device used when the patient sleeps, this is the first medical device used when the patient is awake, and it is designed to improve tongue muscle function and help prevent the tongue from collapsing back while sleeping, thus blocking the air passage.
(Pharmaceutical Mingkangde) Coxing Zhongwei new crown inactivated vaccine approved in China on February 5, NMPA conditions approved Beijing Koxing Zhongwei Biotechnology Co., Ltd. new coronavirus inactivated vaccine registration application.
the vaccine is suitable for preventing diseases caused by new coronavirus infections.
, NMPA has approved two new crown vaccines, the first of which is the new coronavirus pneumonia inactivated vaccine for Chinese organisms of the National Pharmaceutical Group.
(Pharmaceutical Mingkangde) Hainan Hai Pharmaceuticals: Subsidiary Amoxilin Capsules through generic drug consistency evaluation February 7, Hainan Hai Pharmaceuticals announced that its holding subsidiary recently obtained NMPA approved the issuance of the chemical "Amoxilin Capsules" "Drug Supplemental Application Approval Notice."
amoxicillin capsules are mainly used for the treatment of infectious diseases in adults and children caused by sensitive bacteria.
(Hainan Hai Pharmaceutical Announcement) Yuekang Pharmaceuticals: Amoxilin capsules through generic drug consistency evaluation February 7, Yuekang Pharmaceuticals announcement, Amoxilin capsules through generic drug consistency evaluation.
the drug is widely used in the treatment of upper respiratory tract infections caused by sensitive bacteria, genitourinary tract infections, skin soft tissue infections, lower respiratory tract infections and the eradication of Helicobacteria in association with other drugs.
(Yuekang Pharmaceutical Announcement) Huabang Health: The drug registration approval for amino salginate intestinal soluble particles was the first in the country on February 7, Huabang Health Announcement, a wholly-owned subsidiary Huabang Pharmaceuticals obtained the approval of the State Drug Administration issued on the amino sulphate intestinal soluble particles "drug registration approval."
amino saliotic acid as a tuberculosis treatment drug, Huabang Pharmaceuticals is the first company in the country to obtain a drug for amino saliotic acid intestinal soluble particles registered approval.
(Huabang Health) BaiOtai: Scucciyu single anti-injection clinical trial was approved on February 7, Bai otai announced that the company recently approved by the NMPA issued the company in the research drug Skuchiyu monoanti (BAT2306) injection "Clinical Trial Approval Notice."
reviewed, the Skuchiyu monoantigen injection received on December 3, 2020 met the requirements for drug registration and agreed to conduct clinical trials.
(Beotai Announcement) Hundred Times Meishi Guibao injection with Rotsip listing application was accepted to be priority review February 6, CDE official website shows that Shishi Shiguibao pharmaceutical subsidiary Xinji Pharmaceutical "Injection Rotsip" in the domestic market application and was accepted.
the drug is a red blood cell ripening agent for adult β-thalassemia patients who need regular infusions of red blood cells.
(Insight database) cyclophenol third listing application was accepted on February 6, according to the CDE official website, Hesco Pharmaceutical cyclophenol injection class 2.4 new drug application was accepted, this is the third listed application submitted by cyclophenol injection in China, the relevant people speculated that the registration of the adaptation is: fiber bronchoscopy sedation and/or anesthesia.
(CPhl Pharmaceuticals Online) Dechi Pharmaceuticals selinexor is to be included in the priority review of the treatment of multiple myeloma NMPA Drug Review Center latest publicity, Deqi Pharmaceuticals ATG-010 (selinexor) tablet listing application has been included in the proposed priority review list, intended for the treatment of relapse or refracing multiple myeloma.
public information, the application for the ATG-010 to be included in the CDE's priority review is its fifth application for a new drug to be marketed in the Asia Pacific region.
(Pharmaceutical) AbbVie IL-23 inhibitors approved in China Clinical NMPA Drug Review Center latest publicity shows that AbbVie's IL-23 inhibitors Risankizumab injections have been approved in two clinical trials for the treatment of moderate to severe Crohn's disease.
it's worth noting that AbbVie recently announced that risankizumab has reached the primary endpoint of the induction phase in two Phase 3 clinical trials for adult patients with moderate to severe Crohn's disease.
(Pharmaceutical Mission) can be whole-body drug-based new pancreatic cancer lysovirus therapy recently, researchers from Queen Mary University of London and Zhengzhou University developed a systemic drug treatment platform for the treatment of pancreatic cancer using the lysolytic bovine pox virus.
the virus has been improved to improve its safety, spread within and between tumors, and activate an effective anti-tumor immune response, in association with ICI significantly extended the survival of preclinical model animals of pancreatic cancer.
study was published on January 27th in Journal for ImmunoTherapy of Cancer.
(Pharmaceutical Rubik's Cube) in the successful research and development of two cold chain disinfectant formula February 7, the Chinese CDC successfully developed two low-temperature disinfectant formulations, including -18 degrees C low-temperature disinfectants and -40 degrees C low-temperature disinfectants, suitable for low-temperature environment and the surface disinfection of the packaging surface of articles.
In January 2021, the application pilot was carried out in The city of Weifenhe, Heilongjiang Province, and Qingdao City, Shandong Province, and the results showed that the production process of low-temperature disinfectants developed was simple, the raw material cost was low, the disinfection effect was reliable at low temperature, and the disinfection problem of low-temperature environment and the packaging of frozen articles in the high-cold areas of the north could be effectively solved.
(Caixin)